No matches
Type 2 Inflammation

AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

Experts from different specialties use a case-based discussion to understand type 2 inflammatory diseases from a nurse practitioner perspective.
Lakshi Aldredge
Miguel Lanz
Angela Bretton
ANP-BC, DCNP, FAANP, MSN
Lakshi Aldredge +3 more

Related resources

UEGW 2023 | Biologics in EoE

UEGW 2023 | Biologics in EoE

expert video
UEGW 2023 | Burden of EoE and Multidimensional Assessment of Disease

UEGW 2023 | Burden of EoE and Multidimensional Assessment of Disease

expert video
UEGW 2023 | Expanding Horizons in EoE: The Journey to Long-term Disease Control

UEGW 2023 | Expanding Horizons in EoE: The Journey to Long-term Disease Control

expert video
UEGW 2023 | How Do You and Your Patient Decide What Is Best for Managing Their EoE?

UEGW 2023 | How Do You and Your Patient Decide What Is Best for Managing Their EoE?

expert video
UEGW 2023 | How Do You Individualize the Approach to Assessing EoE?

UEGW 2023 | How Do You Individualize the Approach to Assessing EoE?

expert video
ERS 2023 | Adult Asthma Symposium: Mini Debate

ERS 2023 | Adult Asthma Symposium: Mini Debate

expert video
ERS 2023 | Adult Asthma Symposium: Panel Discussion

ERS 2023 | Adult Asthma Symposium: Panel Discussion

expert video
ERS 2023 | Advancing Asthma Management Beyond Control

ERS 2023 | Advancing Asthma Management Beyond Control

expert video
ERS 2023 | Assessing Disease Activity to Better Define On-Treatment Clinical Remission in Pediatric Severe Asthma

ERS 2023 | Assessing Disease Activity to Better Define On-Treatment Clinical Remission in Pediatric Severe Asthma

expert video
ERS 2023 | Burden of Underlying Disease in Pediatric Severe Asthma

ERS 2023 | Burden of Underlying Disease in Pediatric Severe Asthma

expert video
ERS 2023 | Evolving Patient Care: From Symptom Control to On-Treatment ​Clinical Remission​

ERS 2023 | Evolving Patient Care: From Symptom Control to On-Treatment ​Clinical Remission​

expert video
ERS 2023 | How Achievable Is Clinical Remission on Biologic Therapy?

ERS 2023 | How Achievable Is Clinical Remission on Biologic Therapy?

expert video
ERS 2023 | On-Therapy Remission in Pediatric Asthma: Where Are We Today?

ERS 2023 | On-Therapy Remission in Pediatric Asthma: Where Are We Today?

expert video
ERS 2023 | Pediatric Asthma Symposium: Patient Case Discussion

ERS 2023 | Pediatric Asthma Symposium: Patient Case Discussion

expert video
ERS 2023 | Progression of Underlying Disease in Pediatric Severe Asthma

ERS 2023 | Progression of Underlying Disease in Pediatric Severe Asthma

expert video
ERS 2023 | Type 2 Biomarkers as Predictive and Prognostic Tools to Guide Management

ERS 2023 | Type 2 Biomarkers as Predictive and Prognostic Tools to Guide Management

expert video
Type 2 Inflammation in EoE and Impact on Disease Burden

Type 2 Inflammation in EoE and Impact on Disease Burden

expert video
IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective

IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective

expert video
Multidisciplinary Partnership for Type 2 Inflammatory Diseases

Multidisciplinary Partnership for Type 2 Inflammatory Diseases

expert video
Overview of EoE Pathophysiology and the Impact on Patient Burden

Overview of EoE Pathophysiology and the Impact on Patient Burden

expert video
ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

expert video
ESPGHAN 2024 | Burden and Timely Recognition of Pediatric EoE

ESPGHAN 2024 | Burden and Timely Recognition of Pediatric EoE

expert video
ESPGHAN 2024 | Clinical Management of Young Children With EoE

ESPGHAN 2024 | Clinical Management of Young Children With EoE

expert video
ADVENT On Air | Dysphagia in EoE: How Can You See Beyond Patients’ Adaptive Behaviors?

ADVENT On Air | Dysphagia in EoE: How Can You See Beyond Patients’ Adaptive Behaviors?

Podcast
ADVENT On Air | More Than Just Difficulty Swallowing: EoE Burden and Diagnosis

ADVENT On Air | More Than Just Difficulty Swallowing: EoE Burden and Diagnosis

Podcast
Adaptive Behaviors in EoE Infographic

Adaptive Behaviors in EoE Infographic

Infographic
Assessing EoE: Monitoring Patients With EoE in Clinical Practice

Assessing EoE: Monitoring Patients With EoE in Clinical Practice

expert video
Type 2 Inflammation Underpins Pediatric Severe Asthma

Type 2 Inflammation Underpins Pediatric Severe Asthma

Infographic
ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

expert video
GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

interactivity
Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD

Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD

expert video
IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

expert video
IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

expert video
IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

expert video
ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?

ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?

Podcast
ADVENT On Air | Loss of Smell in CRSwNP Patients

ADVENT On Air | Loss of Smell in CRSwNP Patients

Podcast
ADVENT On Air | Remission in CRSwNP

ADVENT On Air | Remission in CRSwNP

Podcast
Role of Type 2 Inflammation Across Different Chronic Diseases

Role of Type 2 Inflammation Across Different Chronic Diseases

expert video
Trajectories of Type 2 Inflammation in Pediatric Patients

Trajectories of Type 2 Inflammation in Pediatric Patients

expert video
Evolving Topics in Type 2 Inflammation

Evolving Topics in Type 2 Inflammation

expert video
Connecting the Dots from Type 2 Inflammation to Patient Perspectives

Connecting the Dots from Type 2 Inflammation to Patient Perspectives

expert video
ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

Podcast
How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

expert video
Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?

Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?

expert video
Dr. Giorgio Canonica Regarding Multidisciplinary Approach

Dr. Giorgio Canonica Regarding Multidisciplinary Approach

expert video
Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?

Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?

expert video
Eosinophils as a Biomarker for Type 2 Asthma

Eosinophils as a Biomarker for Type 2 Asthma

expert video
Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

expert video
ERS 2024 | Understanding the Complex Pathophysiology of COPD

ERS 2024 | Understanding the Complex Pathophysiology of COPD

expert video
COPD and Asthma: What's the Difference and Is There a Link?

COPD and Asthma: What's the Difference and Is There a Link?

interactivity

Learning objectives

  • Recognize common clinical signs and symptoms of type 2 inflammatory diseases seen in primary care and determine when to refer to a specialist
  • Understand the common underlying pathophysiology of type 2 inflammation in multiple atopic diseases​
  • Explore the impact of multimorbidity on patient burden and apply collaborative strategies to optimize care

Description

Lakshi Aldredge, Angela Bretton, Miguel Lanz, and Hilary Ugras use a collaborative case-based panel discussion to explore the interconnected nature of chronic underlying type 2 inflammation and its profound impact across multiple diseases and share insights that can be applied in clinical practice to optimize collaborative patient care.

Tags
type 2 inflammationsymptomsth2 polarizationquality of lifemultidisciplinary carecoexisting diseasesdiagnosispatient caseupper airwaylower airwayloss of smellitchfev1
MAT-GLB-2504896 - 1.0 - 09/2025

About these experts

Dermatology
ANP-BC, DCNP, FAANP, MSN

Lakshi Aldredge

Director for the Primary Care NP Residency Program, VA Portland Health System | Portland, OR

Allergy/Immunology
MD, FAAAAI

Miguel Lanz

Lanz Allergy, Asthma & Immunology AAADRS Clinical Research Center | Coral Gables, FL

Allergy/Immunology
APRN, FNP-BC, MSN

Angela Bretton

San Diego Allergy and Immunology | Vista, CA

Gastroenterology
FNP-BC, MSN

Hilary Ugras

Beth Israel Deaconess Medical Center | Boston, MA

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: AustriaChange country/region